This study will test the hypothesis that daily subcuaneous administration of 20µg of
teriparatide (TPTD) as compared to daily subcuaneous placebo for twelve weeks accelerates
proximal 2-segment humerus fracture healing and improves the three dimensional structural
properties of bone as measured via quantitative bone image analysis and finite element
modeling assessed by quantitative computed tomography.